Chronic lymphatic leukemia - Current therapeutic concepts;Chronische lymphatische leukämie: Aktuelle therapiekonzepte

Internist

Volumn 43, Issue 10, 2002, Pages 1245-1254

  Hallek, M ^a,b   Bergmann, M ^a   Brittinger, G ^a   Dohner H ^a   Dreger, P ^a   Herold, M ^a   Hopfinger, G ^a   Jager U ^a   Knauf, W ^a   Nerl, C ^a   Rummel, M ^a   Schmitt, B ^a   Wendtner, C M ^a   Emmerich, B ^a  

^a Deutsche CLL Studiengruppe ^*  (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BENDAMUSTINE; BRYOSTATIN; CD40 LIGAND MONOCLONAL ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DEPSIPEPTIDE; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBLIMERSEN; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG INDICATION; HUMAN; INFECTION PREVENTION; OPPORTUNISTIC INFECTION; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; CLASSIFICATION; COMPARATIVE STUDY; DOSE RESPONSE; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0036824220     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-002-0707-5     Document Type: Review

References (70)

1. Hallek M, Bergmann M, Emmerich B (2002) Chronische lymphatische Leukämie: aktualisierte Vorschläge zu Diagnostik und Therapie. Dtsch Ärztebl 99: A1294-1301
2. Hallek M, Emmerich B (2001) Chronische lymphatische Leukämie. Uni-Med, Bremen
3. Binet JL, Auquier A, Dighiero G et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234
5. Hallek M, Kuhn-Hallek I, Emmerich B (1997) Prognostic factors in chronic lymphocytic leukemia. Leukemia 11 (Suppl): S4-S13
6. Zwiebel JA, Cheson BD (1998) Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25: 42-59
7. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997
8. Schultze JL, Donovan JW, Gribben JG (1999) Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 77: 259-265
9. CLL trialists' collaborative group (1999) Chemotherapeutic options in chronic lymhocytic leukemia. J Natl Cancer Inst 91: 861-868
10. Wilhelm M, Tony HP, Rueckle-Lanz H, Wilms K (1997) First-line therapy of advanced chronic lymphatic leukemia. Leukemia 11 (Suppl): S14-S18
11. Jaksic B, Brugiatelli M, Krc I et al. (1997) High dose chlorambucil versus Binet's modified cydophosphamide, doxorubicin, vincristin, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Cancer 79: 2107-2114
12. Keating MJ, Kantarjian H, O'Brien S et al. (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9: 44-49
13. Keating M (1999) Improving the complete remission rate in chronic lymphocytic leukemia. Am Soc Hematol, 262-269
14. Keating MJ, O'Brien S, Lerner S et al. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92: 1165-71
15. Angelopoulou MA, Poziopoulos C, Boussiotis VA, Kontopidou F, Pangalis GA (1996) Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response. Leuk Lymphoma 21: 321-324
16. Montserrat E, Lopez-Lorenzo JL, Manso F et al. (1996) Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma 21: 467-472
17. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 15: 458-465
18. Rai KR, Peterson BL, Appelbaum FR et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757
19. French Cooperative Group on CLL (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicine, and prednisone (CAP) fortreatment of advanced-stage chronic lymphocytic leukemia. Lancet 347: 1432-1438
20. Leporrier M, Chevret S, Cazin B et al. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98: 2319-2325
21. Cheson BD (1998) Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation. Semin Hematol 35: 14-21
22. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129: 559-566
23. Juliusson G (1997) Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 39 (Suppl): S41-S4
24. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM (1998) Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16: 2313-2320
25. Juliusson G, Christiansen I, Hansen MM, Johnsen S, Kimby E, Elmhorn-Rosenborg A, Liliemark J (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14: 2160-2166
26. Robak T, Blonski JZ, Kasznicki M et al. (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96: 2723-2729
27. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13: 570-574
28. Rai KR, Peterson BL, Appelbaum FR et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757
29. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 (Suppl): 66-73
30. Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26 (Suppl): 52-57
31. Huhn D, von Schilling C, Wilhelm M et al. for the GCLLSG (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98: 1326-1331
32. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62: 76-82
33. Byrd J, Murphy T, Howard R et al. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153-2164
34. O'Brien S, Kantarijan H, Thomas D et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 19: 2165-2170
35. Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK, Wilhelm M (2001) Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 98: 1991-1992
36. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224
37. Tang SC, Hewitt K, Reis MD, Berinstein NL (1996) Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 24: 93-101
38. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15: 1567-1574
39. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93: 151-153
40. Dyer MJ, Kelsey SM, Mackay HJ et al. (1997) In vivo "purging" of residual disease in CLL with Campath-1H. Br J Haematol 97: 669-672
41. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94: 2836-2843
42. Flinn IW, Byrd JC, Morrison C et al. (2000) Fludarabine and cyclophosphamide with filgastrim support in patients with previously untreated indolent lymphoid malignancies. Blood 96: 71-75
43. Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S (1999) Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 104: 612-613
44. Hallek M, Schmitt B, Wilhelm M et al. and Germany CLL Study Group (2001) Fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia: Results of a phase II study (CLL2 protocol) of the German CLL Study Group (GCLLSG). Br J Haematol 114: 342-348
45. O'Brien S, Kantarjian H, Cortes J et al. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19: 1414-1420
46. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M (1997) Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 59: 327-328
47. Rummel MJ, Kafer G, Pfreundschuh M et al. (1999) Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 10: 183-188
48. Bosch F, Ferrer A, Lopez-Guillermo A et al. (2001) Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukaemia (CLL): final results of a phase II study. Blood 98 (Suppl): abstr 2655
49. Wierda W, O'Brien S, Albitar M et al. (2001) Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98 (Suppl): abstr 3210
50. Byrd J, Peterson B, Park K et al. (2001) Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphyocytic leukemia (CLL) patients: results from CALGB 9712. Blood 98 (Suppl): abstr 3212
51. Manero GG, O'Brien S, Cortes J et al. (2001) Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) Blood 98 (Suppl): abstr 2650
52. Schulz H, Klein S, Rehwald U et al. (2001) Phase II-study of rituximab in combination with fludarabine in patients with chronic lymphocytic leukemia (CLL). Blood 98 (Suppl): abstr 1534
53. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245-2247
54. Byrd JC, Grever MR (2001) Finding new therapies for patients with chronic lymphocytic leukemia. In: Cheson B (ed) Chronic lymphoid leukemias. Marcel Dekker, New York, pp 417-434
55. Wendtner CM, Kurzeder C, Kofler D, Edbauer D, Buhmann R, Hallek M (2001) Innovative Therapieansätze. Hallek M, Emmerich B (Hrsg) Chronische lymphatische Leukämie. Uni-Med, Bremen, S 116-122
56. Anger C, Fink R, Fleischer J (1975) Vergleichsuntersuchung zwischen Cytostasan (Bendamustin) und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom. Dtsch Gesundheitswes 30: 1280-1285
57. Heider M, Gauler T, Niederle N (1999) Efficacy and toxicity of bendamustine in patients with relapsed low grade non-Hodgkin's lymphoma (NHL). Ann Oncol 10 (Suppl): 124
58. Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127: 48-54
59. Dreger P, Michallet M, Schmitz N (2000) Stemcell transplantation for chronic lymphocytic leukemia: the 1999 perspective. Ann Oncol 11 (Suppl): 49-53
60. Meloni G, Proia A, Mauro A et al. (2000) Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica 85: 952-960
61. Waselenko JK, Flynn JM, Byrd JC (1999) Stemcell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived. Semin Oncol 26: 48-61
62. Khouri IF, Keating M, Korbling M et al. (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16: 2817-2824
63. Gribben JG (1999) Stem-cell transplantation for indolent lymphoma. Semin Hematol 36 (Suppl): 18-25
64. Toze CL, Shepherd JD, Connors JM et al. (2000) Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 25: 605-612
65. Molica S (1994) Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 13: 203-214
66. Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25: 98-106
67. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in chronic lymphocytic leukemia. N Engl J Med 319: 902-907
68. Diehl LF, Ketchum LH (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25: 80-97
69. Zimmer-Molsberger B, Knauf W, Thiel E (1997) Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet 350: 1003-1004
70. George JN, Woolf JH, Raskob GE et al. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88: 3-40